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The Gout
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Abstract
Gout is a form of arthritis in an individual accompanied with symptoms like 
severe pain, stiffness, and swelling of one or more joints. Factors that influence 
rates of gout are many like drinking alcohol, being overweight, drinking soda, 
becoming dehydrated, the weather, poorly fitting shoes, medical treatments, and 
many more. The root cause of this condition mainly we can say is the disorder of 
purine metabolism. There are diagnostic options like synovial fluid test, blood 
test for uric acid, and differential diagnosis. Preventive measures can include both 
lifestyle changes and medications. In a recent trend, many treatment options are 
available like the use of NSAIDs, colchicine, steroids, etc. Common drugs which 
are on use are probenecid, allopurinol, febuxostat, and pegloticase. Our medical 
fraternity and researchers are continuing to work on further development.
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1. Introduction
Gout is a disease condition which often is considered as a form of inflammatory 
arthritis [1–4]. Unlike arthritis, gout is not a degenerative process. It’s generally 
characterized by frequent attacks of swelling [5, 6], redness, and a tender, warm, 
and puffy expression of bone joint areas. Figures 1–3 represent a few gouty expres-
sions. The joints of limbs especially lower limbs, at the base part of the big toe and 
at the first joint of forefingers of upper limbs, are affected. Some other complica-
tions associated are like tophus, urate nephropathy, or kidney stones.
Gout is the result of persistently increased levels of uric acid in the blood [7]. An 
enzyme named xanthine oxidase is mainly responsible for the production of uric 
acid in our body. Figure 4 explains the synthesis pathway of uric acid. As the uric 
acid concentration becomes high, it undergoes crystallization, and the crystals get 
deposited in joints. Thus, the surrounding tissues get affected which may lead to 
redness, swelling, and inflammation, resulting in an attack of gout.
2. Cause
Gout is a result of a disorder in purine metabolism. When there is an increase 
in the uric acid level in blood, there is a chance of crystallization of uric acid. Such 
crystals are deposited in joints which start showing the symptoms of gout. The 
predominant reason of increased level of blood urea is the reduced amount of 
excretion of uric acid from the body. Synthesis of excessive amount of uric acid 
may be another reason for increased level in blood, but the cases are more where 
the first reason is predominant. The risk of developing the symptoms is more 
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and faster as the concentration of uric acid increases. The normal uric acid level 
in the human body is 2.4–6.0 mg/dL in the case of female and 3.4–7.0 mg/dL in 
the case of male. When levels are between approximately 7 and 8.9 mg/dL, the 
Figure 1. 
Swelling in the knee.
Figure 2. 
Puffy wrist (ulna).
3The Gout
DOI: http://dx.doi.org/10.5772/intechopen.90540
Figure 3. 
Swelling and stiff finger.
Figure 4. 
Part of uric acid pathway.
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approximate risk is 0.5% per year. The risk may extend up to 4.5% in those with a 
level more than 9 mg/dL [8].
Uric acid, when it is in higher level in blood, crystallizes in the form of a salt, 
monosodium urate, precipitating and making deposition in joints, on tendons, 
and also in the surrounding tissues. These deposits may be walled off by the ring 
of certain proteins, which can block the interaction of these crystals with cells and 
therefore can avoid inflammation. Crystals may break and be displaced out due to 
the minor physical stress-related damage to the joint like medical or surgical stress 
or otherwise rapid changes in uric acid levels or so. When they disintegrate through 
the tophi, they stimulate a local immune-mediated physical-chemical inflammatory 
reaction in macrophages. This is initiated by an inflammation-mediating protein 
complex named NLRP3. In the mechanism of inflammation, a protein named inter-
leukin 1β plays an important role which is obtained from pro-interleukin 1β with the 
help of enzyme caspase 1. NLRP3 assists the enzyme in its function.
3. Diagnosis
Sign and symptoms of arthritis may motivate the physician to go for examina-
tion of the patient. It can be diagnosed by different investigational methods. 
Patients with hyperuricemia can receive treatment based on the diagnosis and their 
severity. Different types of diagnosis are mentioned as follows.
3.1 Blood tests
Since hyperuricemia is a cause for uric acid crystallization and deposition of 
the same on joints, examination of blood sample is a common and initial process 
observed in orthopedic clinics [9, 10]. But sometimes it’s observed that gout occurs 
without hyperuricemia also and many people with increased uric acid levels did not 
develop gout. Thus, the usefulness of the diagnosis of measuring uric acid levels in 
many individuals is limited. The normal uric acid level in blood is ranging around or 
less than 420 μmol/L (7.0 mg/dL) in males and 360 μmol/L (6.0 mg/dL) in females. 
Therefore, above this margin of uric acid in blood may be considered as hyperuri-
cemia. Other blood sample investigations commonly performed are erythrocyte 
sedimentation rate (ESR), white blood cell count, kidney function and electrolyte 
tests.
3.2 Synovial fluid
A qualitative investigation of gout is based upon polarimetric analysis of crystals 
of monosodium urate [11]. These crystals are deposited on the joints of a hyper-
uricemic patient. A synovial fluid sample is collected from undiagnosed inflamed 
joints with the help of arthrocentesis. The fluid is sampled appropriately to exam-
ine these crystals. In a polarimeter the sample is studied to check the needle-like 
morphology as well as strong negative birefringence.
3.3 Miscellaneous methods
There are certain investigations which may or may not be directly related 
to arthritis but definitely prove beneficial most of the time [12]. Detection for 
psoriatic arthritis is one of them. Since it can affect joints on either one side or 
both sides of our body, the signs and symptoms of this often resemble those of 
arthritis. The disease causes joints to become painful, swollen, puffy, and warm 
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to the touch. Another important test is for septic arthritis. This may be accompa-
nied by joint infection. Naturally the disease results in joint inflammation. Other 
symptoms typically include heat, redness, and pain in a single joint which may 
be associated with a decreased ability in moving the joint. One more diagnosis 
may be recommended, and that is to test for reactive arthritis. This can affect 
the heels, fingers, toes, low back portion, and joints, especially of the ankles and 
knees [13, 14].
4. Preventive measures
In mild to moderate cases of gout, lifestyle changes can decrease uric acid levels 
in blood. These modifications may include selection of correct diet, regular and 
appropriate exercise, and consultation with a physician. Physiotherapy also can help 
in this regard.
4.1 Food habit
Appropriate diet is very important [15]. Overweight is a big factor causing joint 
pain [16]. Food containing high amounts of purine such as seafood like shellfish, 
anchovies, sardines, herring, codfish, mussels, scallops, trout haddock, etc.; some 
meats, such as turkey, bacon, veal, venison, and organ meats like liver, etc. [17]; and 
drinks and beverages like beer or all types of alcoholic beverages, containing high 
amounts of purine, can increase blood urea level [18]. Soft drink contains either 
fructose or sucrose in huge quantity which may enhance the precipitation of uric 
acid crystals. Therefore, reducing or omitting such products from the diet list is 
advisable.
4.2 Sleep apnea
As there is a chance of deficiency of oxygen in the cell due to improper breathing 
or irregular breathing style during sleep, it may stimulate the release of purine from 
those cells, and therefore a control on sleep apnea may help in the control of gout.
4.3 Dehydration
Becoming dehydrated may also be a reason of gout risk. Exact mechanism is not 
clear, but it is believed that it may increase the concentration of uric acid in reduced 
volume of blood and also in the joint fluid. Hence, consuming adequate amount of 
water is advisable.
4.4 Obesity
Obesity, diabetes, and increased cholesterol are conditions quite commonly seen 
together. If these two disorders become contemporary in a patient, he or she may 
land up with a metabolic syndrome. Such patients frequently also have an elevated 
level of uric acid in their blood. In certain time diuretics prescribed to control high 
blood pressure also can cause higher levels of uric acid.
4.5 Drinking soda
Carbonated water for drinks or drinking soda has a high-fructose corn syrup 
which is a culprit in elevating uric acid levels, thereby increasing gout risk.
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4.6 Kidney stones
In a certain time, kidney stone may get traces of uric acid. In such cases if dehy-
dration takes place in the patient’s body, then precipitation of uric acid becomes 
more severe. To prevent dehydration, drinking sufficient amount of water a day is 
very essential.
4.7 Poorly fitting shoes
Wearing the wrong shoes can become another gout-triggering factor. Any kind 
of trauma or damage to an area can cause a gout pain and swelling in susceptible 
people. If our shoes rub the toe or nearby area of our feet, then it can contribute to a 
gout attack. So it is better to make sure that the toe area of our shoes is wide enough 
so that it can accommodate our feet without pinching or rubbing.
4.8 Medical treatments
Toxic effect of some drug substances can contribute in hyperuricemia. These 
drug substances are recommended for patients for certain disease conditions where 
they are certainly beneficial but may result in elevated uric acid level. Diuretics can 
decrease the removal of uric acid from our body and cause hyperuricemia, thereby 
a risk factor to develop gout. In the treatment of carcinoma, chemotherapy may 
lead to the breakdown and rapid turnover of tissue cells and can lead to increased 
synthesis of uric acid. In case of surgery, a sudden severe physiological change that 
causes reduced blood flowing to the area of peripheral joints can also be a risk factor 
for gout. Therefore, adequate amounts of precautions are required while receiving 
treatment.
5. Medications
Many drug substances are available for the treatment of hyperuricemia. As a 
first-line therapy along with these drugs, a compound is to be recommended which 
can cause a symptomatic relief. One of the best choices is an anti-inflammatory 
agent.
Available drugs recommended for reducing hyperuricemia are allopurinol, 
febuxostat, probenecid, pegloticase, lesinurad, etc.
Allopurinol is a structural isomer of hypoxanthine (a naturally existing purine 
in our body) and acts to inhibit an enzyme xanthine oxidase [19]. In the presence 
of this enzyme, allopurinol will be converted to a compound named alloxanthine, 
and thereby the formation of uric acid from hypoxanthine and xanthine will be 
inhibited.
Febuxostat is not a purine-based compound but a selective inhibitor of enzyme 
xanthine oxidase [20–24]. In contrast to allopurinol, this compound inhibits both 
oxidized and reduced forms of enzyme xanthine oxidase and has minimal effects 
on other enzymes of pyrimidine and purine metabolism. A study comparing 
febuxostat to allopurinol revealed that more individuals receiving febuxostat had a 
decreased uric acid level.
Therapeutically, probenecid is generally coadministered with other pharmaco-
logically active substances such as anti-inflammatory drugs or penicillins resulting 
in a substantial diminished renal clearance of all these compounds [25–28]. In 
higher doses than are actually required for the uricosuric effect, probenecid can 
inhibit the transport system which removes acid substances from the cerebrospinal 
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fluid. Probenecid also increases the urinary excretion of uric acid and therefore has 
a therapeutic value for the ailment of gout.
Pegloticase is a third-line treatment option for those in whom other treatment 
options are not tolerated [29]. Generally it is an option for the treatment of chronic, 
severe, treatment-refractory gout. Pegloticase, a PEGylated, recombinant uricase 
enzyme, converts salt of uric acid into allantoin. Thus, it makes a wonderful job by 
increasing the excretion of uric acid through kidney filtration.
Lesinurad is a drug of choice to be recommended together with either febuxostat 
or allopurinol when these medications are not sufficient as monotherapy [30, 31]. 
It reduces urate transport by inhibiting a protein named URAT1 that is responsible 
for much reabsorption of uric acid or urat in the kidneys. It also inhibits the OAT4 
protein, which is associated with hyperuricemic condition caused by diuretic drugs.
A confirmation about a gout case is given by medical experts only after certain 
tests are conducted and analyzed. Prior to the investigation, a physician can go 
for a symptomatic relief for the suffering patients by providing a simple prescrip-
tion containing simple anti-inflammatory or analgesic drugs (NSAIDs) [32, 33]. 
Common compounds are like acetaminophen, ibuprofen, indomethacin, ketorolac, 
piroxicam, mefenamic acid, etc. A selective COX-2 inhibitor can be a better choice 
in case a physician looks for the therapy for beyond 1 week. These drugs include 
meloxicam, celecoxib, rofecoxib, etoricoxib, etc. All the abovementioned drugs 
come under nonsteroidal anti-inflammatory drugs. With similar efficacy cortico-
steroidal drugs also are also recommended as a co-prescription for symptomatic 
control. Both glucocorticoids and mineralocorticoids can be prescribed depending 
on the case demand. Some examples of synthetic corticosteroids are betametha-
sone, prednisone, prednisolone, triamcinolone, methylprednisolone, dexametha-
sone, and systemic (oral and injectable) steroids that are available for use including 
hydrocortisone, cortisone ethamethasoneb, fludrocortisone, etc. For those patients 
unable to tolerate NSAIDs, colchicine is an ideal alternative. Colchicine is a category 
of substance which is effective at lower dose, and it is well tolerated [34]. It may 
interact with some other commonly prescribed drug substances, such as erythro-
mycin and atorvastatin, simvastatin, etc.
6. Conclusion
Gout is a form of disease which may be acute or chronic, associated with symp-
toms like severe pain, stiffness, and swelling of one or more joints. It occurs due 
to increased production of uric acid in our body or reduced excretion of the same 
from our body. Such metabolic disorder may arise from poor lifestyle and improper 
food habits. A number of diagnostic options are available and treatment too. But 
it’s always advisable to adapt a healthy food habit, practice physical exercise, and 
continue with physician’s consultation and medication to get rid of this disease 
condition.
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